PKM and bladder transitional cell carcinoma: For instance, the PKM2 inhibitor Shikonin has demonstrated the ability to overcome cisplatin resistance in BLCA by inducing necroptosis, thereby suggesting an alternative approach to enhance the efficacy of chemotherapy (Wang et al., 2018).